Peter Kraft1, Michael K Schuhmann2, Felix Fluri2, Kristina Lorenz2, Alma Zernecke2, Guido Stoll2, Bernhard Nieswandt2, Christoph Kleinschnitz1. 1. From the Department of Neurology (P.K, M.K.S., F.F., G.S., C.K.) and Institute of Clinical Biochemistry and Pathobiochemistry (A.Z.), University Clinics Würzburg, Würzburg, Germany; and Institute of Pharmacology and Toxicology (K.L) and the Rudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine (B.N.), University of Würzburg, Würzburg, Germany. kraft_p1@ukw.de christoph.kleinschnitz@uni-wuerzburg.de. 2. From the Department of Neurology (P.K, M.K.S., F.F., G.S., C.K.) and Institute of Clinical Biochemistry and Pathobiochemistry (A.Z.), University Clinics Würzburg, Würzburg, Germany; and Institute of Pharmacology and Toxicology (K.L) and the Rudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine (B.N.), University of Würzburg, Würzburg, Germany.
Abstract
BACKGROUND AND PURPOSE: Despite the medical and socioeconomic effect of ischemic stroke and extensive preclinical research, treatment options for ischemic stroke are limited. We recently identified and characterized essential steps of thrombus formation in stroke and demonstrated that inhibition of the platelet glycoprotein (GP) receptors Ib and VI, but not IIb/IIIa, protects young and healthy mice from ischemic neurodegeneration. Whether these findings translate to the clinic remains unclear. Considering that the typical stroke patient is elderly with comorbidity, we aimed to analyze the efficacy and safety of novel preclinical antithrombotics in adult and comorbid mice with acute experimental stroke. METHODS: We subjected adult, healthy, atherosclerotic (Ldlr(-/-)), diabetic (streptozotocin treated), and hypertensive (RenTgMK) mice to a 60-minute transient middle cerebral artery occlusion. Animals were pretreated with anti-GPVI antibodies or treated 1 hour after stroke induction with anti-GPIb or anti-GPIIb/IIIa antigen-binding fragments, respectively. Isotype treatment served as control. Twenty-four hours after transient middle cerebral artery occlusion, we visually assessed the intracerebral hemorrhage rate and measured infarct volumes (using 2,3,5-triphenyltetrazolium chloride-stained brain slices) and functional outcome (using Bederson and grip-test scores). RESULTS: GPIb and GPVI inhibition protected the mice from ischemic stroke without increasing bleeding complications. In contrast, GPIIb/IIIa inhibition was not protective but increased the intracerebral hemorrhage rate. CONCLUSIONS: Inhibition of early steps of thrombus formation protects adult and comorbid mice from ischemic stroke. The use of clinically meaningful mouse strains might improve the translation of preclinical stroke research to the clinic.
BACKGROUND AND PURPOSE: Despite the medical and socioeconomic effect of ischemic stroke and extensive preclinical research, treatment options for ischemic stroke are limited. We recently identified and characterized essential steps of thrombus formation in stroke and demonstrated that inhibition of the platelet glycoprotein (GP) receptors Ib and VI, but not IIb/IIIa, protects young and healthy mice from ischemic neurodegeneration. Whether these findings translate to the clinic remains unclear. Considering that the typical strokepatient is elderly with comorbidity, we aimed to analyze the efficacy and safety of novel preclinical antithrombotics in adult and comorbid mice with acute experimental stroke. METHODS: We subjected adult, healthy, atherosclerotic (Ldlr(-/-)), diabetic (streptozotocin treated), and hypertensive (RenTgMK) mice to a 60-minute transient middle cerebral artery occlusion. Animals were pretreated with anti-GPVI antibodies or treated 1 hour after stroke induction with anti-GPIb or anti-GPIIb/IIIa antigen-binding fragments, respectively. Isotype treatment served as control. Twenty-four hours after transient middle cerebral artery occlusion, we visually assessed the intracerebral hemorrhage rate and measured infarct volumes (using 2,3,5-triphenyltetrazolium chloride-stained brain slices) and functional outcome (using Bederson and grip-test scores). RESULTS: GPIb and GPVI inhibition protected the mice from ischemic stroke without increasing bleeding complications. In contrast, GPIIb/IIIa inhibition was not protective but increased the intracerebral hemorrhage rate. CONCLUSIONS: Inhibition of early steps of thrombus formation protects adult and comorbid mice from ischemic stroke. The use of clinically meaningful mouse strains might improve the translation of preclinical stroke research to the clinic.
Authors: Michael K Schuhmann; Peter Kraft; Michael Bieber; Axel Haarmann; György A Homola; Mirko Pham; Bernhard Nieswandt; Guido Stoll Journal: Transl Stroke Res Date: 2018-01-10 Impact factor: 6.829
Authors: Sarah Gelhard; Roxane-Isabelle Kestner; Moritz Armbrust; Helmuth Steinmetz; Christian Foerch; Ferdinand O Bohmann Journal: J Clin Med Date: 2022-06-10 Impact factor: 4.964
Authors: Frederik Denorme; Bhanu Kanth Manne; Irina Portier; Alicia S Eustes; Yasuhiro Kosaka; Benjamin T Kile; Matthew T Rondina; Robert A Campbell Journal: Blood Date: 2020-02-06 Impact factor: 25.476
Authors: Peter Kraft; Michael K Schuhmann; Cornelia Garz; Solveig Jandke; Daniela Urlaub; Stine Mencl; Alma Zernecke; Hans-Jochen Heinze; Roxana O Carare; Christoph Kleinschnitz; Stefanie Schreiber Journal: PLoS One Date: 2017-08-10 Impact factor: 3.240
Authors: Michael K Schuhmann; Josua Guthmann; Guido Stoll; Bernhard Nieswandt; Peter Kraft; Christoph Kleinschnitz Journal: J Neuroinflammation Date: 2017-01-21 Impact factor: 8.322